Elixiron Immunotherapeutics (hong Kong) Ltd.

This study is testing whether a new drug called EI-001 can help improve skin repigmentation in people with non-segmental vitiligo, a condition that causes loss of skin color. The trial will enroll 45 adults and compare the drug against a placebo to see if it safely reduces the ar…